

# Paul Dorian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6340607/publications.pdf>

Version: 2024-02-01

171  
papers

7,798  
citations

61984

43  
h-index

54911

84  
g-index

171  
all docs

171  
docs citations

171  
times ranked

8436  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bystander interventions and survival after exercise-related sudden cardiac arrest: a systematic review. <i>British Journal of Sports Medicine</i> , 2022, 56, 410-416.	6.7	10
2	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, , CIRCEP121010462.	4.8	3
3	Association of Diabetes Duration and Glycemic Control With Stroke Rate in Patients With Atrial Fibrillation and Diabetes: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023643.	3.7	5
4	Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shock-Refractory Out-of-Hospital Cardiac Arrest. <i>Journal of the American Heart Association</i> , 2022, 11, e023958.	3.7	10
5	Responding to Cardiac Arrest in the Community in the Digital Age. <i>Canadian Journal of Cardiology</i> , 2022, 38, 491-501.	1.7	7
6	Establishing a multicenter, preclinical consortium in resuscitation: A pilot experimental trial evaluating epinephrine in cardiac arrest. <i>Resuscitation</i> , 2022, 175, 57-63.	3.0	3
7	COVID-19-Myocarditis and Return to Play: Reflections and Recommendations From a Canadian Working Group. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1165-1174.	1.7	49
8	A Systematic Review of the Risk of Motor Vehicle Collision in Patients With Syncope. <i>Canadian Journal of Cardiology</i> , 2021, 37, 151-161.	1.7	9
9	Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 140, 62-68.	1.6	20
10	Gender-Based Differences in Outcomes Among Resuscitated Patients With Out-of-Hospital Cardiac Arrest. <i>Circulation</i> , 2021, 143, 641-649.	1.6	45
11	Detecting Patients With Nonvalvular Atrial Fibrillation and Atrial Flutter in the Canadian Primary Care Sentinel Surveillance Network: First Steps. <i>CJC Open</i> , 2021, 3, 367-371.	1.5	1
12	Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy- Are there predictors of appropriate therapy?. <i>Heart Rhythm</i> , 2021, 18, 63-70.	0.7	19
13	Cardiac remodeling in middle-aged endurance athletes: relation between signal-averaged electrocardiogram and LV mass. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H316-H322.	3.2	1
14	A Gas-Powered, Patient-Responsive Automatic Resuscitator for Use in Acute Respiratory Failure: A Bench and Experimental Study. <i>Respiratory Care</i> , 2021, 66, 366-377.	1.6	6
15	Multi-centre implementation of an Educational program to improve the Cardiac Arrest diagnostic accuracy of ambulance Telecommunicators and survival outcomes for sudden cardiac arrest victims: the EduCATE study design and methodology. <i>BMC Emergency Medicine</i> , 2021, 21, 26.	1.9	0
16	Evaluating the 12-Lead Electrocardiogram for Diagnosing ARVC in Young Populations: Implications for Preparticipation Screening of Athletes. <i>CJC Open</i> , 2021, 3, 498-503.	1.5	2
17	Symptoms in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2021, 7, 575-577.	3.2	1
18	Exercise in hypertrophic cardiomyopathy: restrict or rethink. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H2101-H2111.	3.2	10

#	ARTICLE	IF	CITATIONS
19	Wearables for cardiac monitoring in athletes: precious metal or fool's gold?. <i>European Heart Journal Digital Health</i> , 2021, 2, 358-360.	1.7	1
20	An Association Between Cardiologist Billing Patterns, Health Care Use, and Outcomes in Cardiac Patients. <i>CJC Open</i> , 2021, 3, 758-768.	1.5	1
21	A Novel Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Biomarker Anti-DSG2 is Absent in Athletes with Right Ventricular Enlargement. <i>CJC Open</i> , 2021, 3, 1413-1418.	1.5	1
22	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1470-1479.	4.5	11
23	Evaluation of the Risk of Stroke Without Anticoagulation Therapy in Men and Women With Atrial Fibrillation Aged 66 to 74 Years Without Other CHA <sub>2</sub> /DS <sub>2</sub> -VASc Factors. <i>JAMA Cardiology</i> , 2021, 6, 918.	6.1	6
24	Atrial structure and function in middle-aged, physically active males and females: A cardiac magnetic resonance study. <i>Clinical Cardiology</i> , 2021, 44, 1467-1474.	1.8	2
25	Predicting Sudden Cardiac Death After Myocardial Infarction. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009422.	4.8	4
26	Association of Cardiology Billing Amounts With Health Care Utilization and Clinical Outcomes in Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021, 10, e020708.	3.7	1
27	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab513.	0.9	4
28	Myocardial strain assessment using cardiovascular magnetic resonance imaging in recipients of implantable cardioverter defibrillators. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 115.	3.3	0
29	Shared Decision Making and the Cardiovascular Care of Athletes: Is It Time to Get Back in the Game?. <i>Canadian Journal of Cardiology</i> , 2020, 36, 941-944.	1.7	11
30	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	2.2	55
31	Field Implementation of Remote Ischemic Conditioning in ST-Segment Elevation Myocardial Infarction: The FIRST Study. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1278-1288.	1.7	9
32	Predicting Sudden Death in Dilated Cardiomyopathy: The Potential Power of Magnetic Resonance Imaging as a Critical Tool. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1006-1008.	1.7	0
33	Cardiac Remodeling in Middle-Aged Endurance Athletes and Recreationally Active Individuals: Challenges in Defining the "Athlete's Heart". <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 247-249.	2.8	7
34	Near-Infrared Spectroscopy to Assess Cerebral Autoregulation and Optimal Mean Arterial Pressure in Patients With Hypoxic-Ischemic Brain Injury: A Prospective Multicenter Feasibility Study. , 2020, 2, e0217.		12
35	Canada-wide mixed methods analysis evaluating the reasons for inappropriate emergency department presentation in patients with a history of atrial fibrillation: the multicentre AF-ED trial. <i>BMJ Open</i> , 2020, 10, e033482.	1.9	3
36	Population Trends in All-Cause Mortality and Cause Specific Death With Incident Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e016810.	3.7	30

#	ARTICLE	IF	CITATIONS
37	Response by Weessler-Snir and Dorian to Letter Regarding Article, "Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario", <i>Circulation</i> , 2020, 141, e703-e704.	1.6	0
38	Common wearable devices demonstrate variable accuracy in measuring heart rate during supraventricular tachycardia. <i>Heart Rhythm</i> , 2020, 17, 854-859.	0.7	25
39	The Role of Quality of Life Indices in Patient-Centred Management of Arrhythmia. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1022-1031.	1.7	4
40	Impact of electrical cardioversion on quality of life for patients with symptomatic persistent atrial fibrillation: Is there a treatment expectation effect?. <i>American Heart Journal</i> , 2020, 226, 152-160.	2.7	3
41	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. <i>Metabolism Open</i> , 2020, 7, 100039.	2.9	14
42	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	3.2	15
43	High risk neighbourhoods: The effect of neighbourhood level factors on cardiac arrest incidence. <i>Resuscitation</i> , 2020, 149, 100-108.	3.0	5
44	Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. <i>Circulation</i> , 2020, 141, 188-198.	1.6	53
45	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007437.	4.8	49
46	Policies to Prevent Sudden Cardiac Death in Young Athletes: Challenging, But More Testing Is Not the Answer. <i>Journal of the American Heart Association</i> , 2020, 9, e016332.	3.7	7
47	Healthcare costs and resource utilization associated with treatment of out-of-hospital cardiac arrest. <i>Resuscitation</i> , 2020, 153, 234-242.	3.0	12
48	Left Ventricular Fibrosis in Middle-Age Athletes and Physically Active Adults. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 2500-2507.	0.4	10
49	Lifestyle modification for the management of atrial fibrillation. <i>Cmaj</i> , 2020, 192, E1469.	2.0	0
50	A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 21-28.	3.0	20
51	Patient-Reported Outcomes in Atrial Fibrillation Research. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 599-605.	3.2	23
52	The prevention and management of sudden cardiac arrest in athletes. <i>Cmaj</i> , 2019, 191, E787-E791.	2.0	13
53	The Potential Impact of Intrathoracic Impedance on Defibrillation Threshold Testing in S-ICDs. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1604.e13-1604.e16.	1.7	1
54	Canadian Cardiovascular Society Cardiovascular Screening of Competitive Athletes: The Utility of the Screening Electrocardiogram to Predict Sudden Cardiac Death. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1557-1566.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario. <i>Circulation</i> , 2019, 140, 1706-1716.	1.6	82
56	Developing a Pan-Canadian Registry of Sudden Cardiac Arrest: Challenges and Opportunities. <i>CJC Open</i> , 2019, 1, 53-61.	1.5	5
57	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1069-1077.	1.7	27
58	Interpreting observational data on adrenaline in cardiac arrest is complicated. <i>Resuscitation</i> , 2019, 138, 314-315.	3.0	0
59	Improving Resuscitation Rates After Out-of-Hospital Cardiac Arrest. <i>Circulation</i> , 2019, 139, 1272-1274.	1.6	1
60	Living alone and cardiovascular disease outcomes. <i>Heart</i> , 2019, 105, 1087-1095.	2.9	26
61	Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 160-168.	1.7	4
62	Prescribing of oral anticoagulants in the emergency department and subsequent long-term use by older adults with atrial fibrillation. <i>Cmaj</i> , 2019, 191, E1345-E1354.	2.0	22
63	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2845-2854.	2.8	94
64	Study of the Effects of Epinephrine on Cerebral Oxygenation and Metabolism During Cardiac Arrest and Resuscitation by Hyperspectral Near-Infrared Spectroscopy. <i>Critical Care Medicine</i> , 2019, 47, e349-e357.	0.9	23
65	Association Between Hospital Teaching Status and Outcomes After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005349.	2.2	12
66	Cardiac effects of CPAP treatment in patients with obstructive sleep apnea and atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 54, 289-297.	1.3	17
67	Canadian Cardiovascular Society/Canadian Heart Rhythm Society Joint Position Statement on the Cardiovascular Screening of Competitive Athletes. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1-11.	1.7	34
68	Clinically Important Drug-Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3552-3559.	0.5	9
69	The STOP-BANG questionnaire shows an insufficient specificity for detecting obstructive sleep apnea in patients with atrial fibrillation. <i>Journal of Sleep Research</i> , 2018, 27, e12702.	3.2	26
70	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients $\geq 75$ Years Versus $< 75$ Years Receiving Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2018, 121, 975-980.	1.6	1
71	Improving Temporal Trends in Survival and Neurological Outcomes After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e003561.	2.2	91
72	Avoiding Clinical Errors With Bedside Echocardiography: A Randomized Clinical Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 88-91.	1.7	2

#	ARTICLE	IF	CITATIONS
73	Management of direct oral anticoagulant associated bleeding: Results of a multinational survey. <i>Thrombosis Research</i> , 2018, 163, 19-21.	1.7	6
74	Sleep Apnea Increases the Risk of New Hospitalized Atrial Fibrillation. <i>Chest</i> , 2018, 154, 1330-1339.	0.8	32
75	Letter by Banks et al Regarding Article, "Does High-Intensity Endurance Training Increase the Risk of Atrial Fibrillation? A Longitudinal Study of Left Atrial Structure and Function" <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006645.	4.8	0
76	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
77	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1371-1392.	1.7	195
78	A Comparison of Two Nights of Ambulatory Sleep Testing in Arrhythmia Patients. <i>Sleep Disorders</i> , 2018, 2018, 1-6.	1.4	9
79	Atrial Fibrillation Clinics in Canada: A Nationwide Project Report. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1219-1224.	1.7	13
80	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 1031-1038.	7.1	24
81	Cardiac MRI and radionuclide ventriculography for measurement of left ventricular ejection fraction in ICD candidates. <i>Magnetic Resonance Imaging</i> , 2018, 52, 69-74.	1.8	3
82	Out-of-Hospital Cardiac Arrest in the Presence of Ischemic Heart Disease: What Is the Long-term Arrhythmic Risk After Revascularization?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1079-1082.	1.7	1
83	The prevalence of obstructive sleep apnea in patients with atrial fibrillation. <i>Clinical Cardiology</i> , 2018, 41, 601-607.	1.8	52
84	A clinical decision instrument to predict 30-day death and cardiovascular hospitalizations after an emergency department visit for atrial fibrillation: The Atrial Fibrillation in the Emergency Room, Part 2 (AFTER2) study. <i>American Heart Journal</i> , 2018, 203, 85-92.	2.7	12
85	Rhythm and rate control of atrial fibrillation in the emergency department "A large community-based observational study. <i>Canadian Journal of Emergency Medicine</i> , 2018, 20, 834-840.	1.1	5
86	Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. <i>Annals of Emergency Medicine</i> , 2017, 69, 562-571.e2.	0.6	51
87	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 737-746.	1.7	58
88	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 582-587.	1.6	8
89	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective. <i>JAMA Cardiology</i> , 2017, 2, 525.	6.1	18
90	Symptoms and Quality of Life After Atrial Fibrillation Ablation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1177-1179.	3.2	2

#	ARTICLE	IF	CITATIONS
91	Implantable Cardioverter Defibrillator Implantation Rates After Out of Hospital Cardiac Arrest: Are the Rates Guideline-Concordant?. Canadian Journal of Cardiology, 2017, 33, 1266-1273.	1.7	6
92	Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest. Circulation, 2017, 136, 2119-2131.	1.6	26
93	Presumed cardiac arrest in children and young adults: A misnomer?. Resuscitation, 2017, 117, 73-79.	3.0	12
94	Prehospital sodium bicarbonate use could worsen long term survival with favorable neurological recovery among patients with out-of-hospital cardiac arrest. Resuscitation, 2017, 119, 63-69.	3.0	25
95	Federal leadership needed to realize national data set for cardiovascular care. Cmaj, 2017, 189, E1294-E1294.	2.0	0
96	Sudden Cardiac Arrest during Participation in Competitive Sports. New England Journal of Medicine, 2017, 377, 1943-1953.	27.0	143
97	Electrocardiograms in Low-Risk Patients Undergoing an Annual Health Examination. JAMA Internal Medicine, 2017, 177, 1326.	5.1	55
98	The impact of hospital experience with out-of-hospital cardiac arrest patients on post cardiac arrest care. Resuscitation, 2017, 110, 169-175.	3.0	19
99	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. Canadian Journal of Cardiology, 2017, 33, 174-188.	1.7	84
100	Cerebral Hemodynamics and Metabolism During Cardiac Arrest and Cardiopulmonary Resuscitation Using Hyperspectral Near Infrared Spectroscopy. Circulation Journal, 2017, 81, 879-887.	1.6	15
101	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. Clinical Pharmacology: Advances and Applications, 2016, Volume 8, 93-107.	1.2	35
102	ECG Features Associated With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation: A Combined AFFIRM and AF-CHF Analysis. Journal of Cardiovascular Electrophysiology, 2016, 27, 404-413.	1.7	6
103	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. Implementation Science, 2016, 11, 159.	6.9	11
104	Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. New England Journal of Medicine, 2016, 374, 1711-1722.	27.0	329
105	Flecainide and elevated liver enzymes in $\alpha$ 1-antitrypsin deficiency. HeartRhythm Case Reports, 2016, 2, 237-240.	0.4	1
106	Trials and tribulations: Antiarrhythmic drugs for the acute conversion of atrial fibrillation. Heart Rhythm, 2016, 13, 1784-1785.	0.7	1
107	2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2016, 32, 1170-1185.	1.7	243
108	Identifying Patients With Atrial Fibrillation in Administrative Data. Canadian Journal of Cardiology, 2016, 32, 1561-1565.	1.7	90

#	ARTICLE	IF	CITATIONS
109	Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. <i>Stroke</i> , 2016, 47, 2380-2385.	2.0	43
110	Assessing arrhythmia risk in a 15-year-old boy whose father died suddenly. <i>Cmaj</i> , 2016, 188, 1172-1174.	2.0	2
111	Factors associated with out-of-hospital cardiac arrest with pulseless electric activity: A population-based study. <i>American Heart Journal</i> , 2016, 177, 129-137.	2.7	23
112	Oral Anticoagulation for Stroke Prevention in Canadian Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry*. <i>Canadian Journal of Cardiology</i> , 2016, 32, 204-210.	1.7	9
113	Predictors and clinical outcomes of inpatient versus ambulatory management after an emergency department visit for atrial fibrillation: A population-based study. <i>American Heart Journal</i> , 2016, 173, 161-169.	2.7	16
114	Canadian Cardiovascular Society Quality Indicators for Heart Failure. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1038.e5-1038.e9.	1.7	13
115	The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. <i>Canadian Journal of Cardiology</i> , 2016, 32, 336-343.	1.7	14
116	Association of prior $\beta$ -blocker use and the outcomes of patients with out-of-hospital cardiac arrest. <i>American Heart Journal</i> , 2015, 170, 1018-1024.e2.	2.7	7
117	Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. <i>Clinical Therapeutics</i> , 2015, 37, 2476-2488.e27.	2.5	7
118	Identifying Predictors of Cumulative Healthcare Costs in Incident Atrial Fibrillation: A Population-Based Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	15
119	A 26-year-old competitive soccer player with syncope. <i>Cmaj</i> , 2015, 187, 1225-1228.	2.0	0
120	The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications. <i>Canadian Journal of Cardiology</i> , 2015, 31, 3-16.	1.7	96
121	Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNF $\alpha$ . <i>Nature Communications</i> , 2015, 6, 6018.	12.8	148
122	Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 179-186.	2.2	90
123	Whom do you believe? The patient or the ECG?. <i>Heart Rhythm</i> , 2015, 12, 666-667.	0.7	1
124	Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke. <i>Stroke</i> , 2015, 46, 936-941.	2.0	157
125	Does location matter? A proposed methodology to evaluate neighbourhood effects on cardiac arrest survival and bystander CPR. <i>Canadian Journal of Emergency Medicine</i> , 2015, 17, 286-294.	1.1	3
126	A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. <i>Annals of Emergency Medicine</i> , 2015, 66, 658-668.e6.	0.6	19



#	ARTICLE	IF	CITATIONS
127	The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. <i>Annals of Emergency Medicine</i> , 2015, 66, 347-354.e2.	0.6	29
128	Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2015, 46, 2830-2837.	2.0	6
129	Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. <i>European Heart Journal</i> , 2014, 35, 1897-1906.	2.2	78
130	2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1114-1130.	1.7	382
131	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2014, 174, 1651.	5.1	118
132	Trends in Short- and Long-Term Survival Among Out-of-Hospital Cardiac Arrest Patients Alive at Hospital Arrival. <i>Circulation</i> , 2014, 130, 1883-1890.	1.6	130
133	Clinical characteristics and outcomes of acute coronary syndrome patients with left anterior hemiblock. <i>Heart</i> , 2014, 100, 1456-1461.	2.9	3
134	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. <i>JACC: Heart Failure</i> , 2014, 2, 623-629.	4.1	72
135	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 896-904.	2.2	52
136	Greater Mortality Risk Among Patients With Delayed Follow-up After Implantable Cardioverter Defibrillator Procedures. <i>Canadian Journal of Cardiology</i> , 2014, 30, 598-605.	1.7	5
137	Characteristics and Evidence-Based Management of Stable Coronary Artery Disease Patients in Canada Compared With the Rest of the World: Insights From the CLARIFY Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 132-137.	1.7	7
138	Resuscitation Outcomes Consortiumâ€œAmiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial. <i>American Heart Journal</i> , 2014, 167, 653-659.e4.	2.7	53
139	The 2013 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Rehabilitation and Exercise and Surgical Coronary Revascularization. <i>Canadian Journal of Cardiology</i> , 2014, 30, 249-263.	1.7	44
140	Applying the Atrial Fibrillation Guidelines Update to Manage Your Patients With Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1241-1244.	1.7	2
141	Regarding manuscript: â€œResuscitation Outcomes Consortiumâ€œAmiodarone, Lidocaine, or Placebo study: Rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trialâ€œ. <i>American Heart Journal</i> , 2014, 168, e19-e20.	2.7	1
142	Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation. <i>Clinical Therapeutics</i> , 2014, 36, 192-210.e20.	2.5	74
143	Î²-Blockers and Atrial Fibrillation: Hypertension and Other Medical Conditions Influencing Their Use. <i>Canadian Journal of Cardiology</i> , 2014, 30, S38-S41.	1.7	11
144	Lack of difference in T wave variability between patients at risk of sudden cardiac death and healthy subjects. <i>Journal of Electrocardiology</i> , 2014, 47, 251-256.	0.9	3

#	ARTICLE	IF	CITATIONS
145	Abstract 20190: Sudden Cardiac Death in the Young is Frequently Associated With Cardiac Disease and Drug Use. <i>Circulation</i> , 2014, 130, .	1.6	0
146	Quality of Life and Functional Capacity in Patients With Atrial Fibrillation and Congestive Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 455-460.	2.8	97
147	Interpreting changes in quality of life in atrial fibrillation: How much change is meaningful?. <i>American Heart Journal</i> , 2013, 166, 381-387.e8.	2.7	76
148	Factors Associated With 90-Day Death After Emergency Department Discharge for Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2013, 61, 539-548.e1.	0.6	53
149	The American Heart Association 2010 Guidelines for the Management of Cardiac Arrest in Pregnancy: Consensus Recommendations on Implementation Strategies. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2011, 33, 858-863.	0.7	30
150	Development and Validation of the Atrial Fibrillation Effect on Quality-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 15-25.	4.8	339
151	Mechanisms Underlying the Lack of Effect of Implantable Cardioverter-Defibrillator Therapy on Mortality in High-Risk Patients With Recent Myocardial Infarction. <i>Circulation</i> , 2010, 122, 2645-2652.	1.6	126
152	Evaluation of Early Complications Related to De Novo Cardioverter Defibrillator Implantation. <i>Journal of the American College of Cardiology</i> , 2010, 55, 774-782.	2.8	222
153	Effective and efficient use of implantable defibrillators: Sometimes it's over when it's over. <i>Cmaj</i> , 2009, 180, 599-600.	2.0	5
154	Validation of a New Simple Scale to Measure Symptoms in Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2009, 2, 218-224.	4.8	145
155	The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. <i>Journal of Cardiovascular Pharmacology</i> , 2007, 50, 35-40.	1.9	106
156	A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF Scale. <i>Canadian Journal of Cardiology</i> , 2006, 22, 383-386.	1.7	79
157	Gender differences and quality of life in atrial fibrillation: The mediating role of depression. <i>Journal of Psychosomatic Research</i> , 2006, 61, 769-774.	2.6	77
158	Psychological Correlates of Quality of Life in Atrial Fibrillation. <i>Quality of Life Research</i> , 2006, 15, 1323-1333.	3.1	66
159	Antiarrhythmic Action of $\beta$ -Blockers: Potential Mechanisms. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, S15-S22.	2.0	54
160	Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. <i>Cmaj</i> , 2004, 171, 1042-1044.	2.0	0
161	The Burden of Atrial Fibrillation: Should We Abandon Antiarrhythmic Drug Therapy?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004, 9, 257-262.	2.0	9
162	Prophylactic Use of an Implantable Cardioverter-Defibrillator after Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2004, 351, 2481-2488.	27.0	1,358

#	ARTICLE	IF	CITATIONS
163	Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. American Heart Journal, 2002, 143, 984-990.	2.7	211
164	Validation of a Noninvasive Measure of Local Myocardial Repolarization in a Conscious Human Model:.. Journal of Cardiovascular Electrophysiology, 1999, 10, 1171-1179.	1.7	4
165	Autonomie Correlates of Antidepressant Treatment Using Heart-Rate Variability Analysis. Canadian Journal of Psychiatry, 1998, 43, 183-186.	1.9	84
166	Transcutaneous T Wave Shock: A Universal Method for Ventricular Fibrillation Induction. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2930-2935.	1.2	16
167	Do Permanent Pacemakers Need an Insulative Coating? Results of a Prospective Randomized Double-Blind Study. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2394-2397.	1.2	0
168	A Population-Based Method for the Estimation of Defibrillation Energy Requirements in Humans. Circulation, 1997, 96, 267-273.	1.6	6
169	Inadvertent Defibrillator Sense/Pace Lead Placement in the Middle Cardiac Vein: A Possible Complication with New Implications. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 2349-2352.	1.2	1
170	Defibrillation Current and Impedance are Determinants of Defibrillation Energy Requirements. PACE - Pacing and Clinical Electrophysiology, 1988, 11, 1996-2001.	1.2	14
171	Triazolam and ethanol interaction: Kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics, 1985, 37, 558-562.	4.7	32